Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7101793 | 1.00 | OPRM1 (0.37) | OPRM1OPRD1OPRK1OPRL1CYP3A4 | |
| SCHEMBL7102084 | 0.98 | ALOX15 (0.38) | OPRM1OPRD1OPRK1OPRL1CYP3A4 | |
| SCHEMBL1703171 | 0.94 | ALOX15 (0.38) | OPRM1OPRD1OPRK1OPRL1CYP3A4 | |
| SCHEMBL29710660 | 0.94 | ALOX15 (0.38) | OPRM1OPRD1OPRK1OPRL1CYP3A4 | |
| SCHEMBL2079404 | 0.89 | ALOX15 (0.41) | OPRM1OPRD1OPRK1OPRL1CYP3A4 | |
| SCHEMBL17733195 | 0.80 | MEN1 (0.41) | CYP3A4ALOX15SMN1; SMN2ADORA3SIGMAR1 | |
| SCHEMBL29484741 | 0.80 | MEN1 (0.41) | CYP3A4ALOX15SMN1; SMN2ADORA3SIGMAR1 | |
| SCHEMBL6058582 | 0.80 | MEN1 (0.41) | CYP3A4ALOX15SMN1; SMN2ADORA3SIGMAR1 | |
| SCHEMBL8222575 | 0.80 | SIGMAR1 (0.57) | OPRM1OPRD1OPRK1OPRL1CYP3A4 | |
| SCHEMBL5349864 | 0.79 | OPRM1 (0.54) | OPRM1OPRD1OPRK1OPRL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1901776-B1 | NOVEL MEDICINAL COMBINATIONS WHICH ARE USED FOR TREATING RESPIRATORY TRACT DISEASES AND CONTAIN BETA-2 LONG-ACTING AGONISTS AND AT LEAST ONE OTHER TYPE OF ACTIVE SUBSTANCE | BOEHRINGER INGELHEIM INT (DE) | 2012-02-22 | — | — | EP | disclosed |
| EP-1856070-B1 | NOVEL DRUGS FOR TREATING RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-20110053926-A1 | New Pharmaceutically-Active Compounds for the Treatment of Respiratory Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| EP-1911749-B1 | New long-working Beta-2 agonists and their use as medicine | BOEHRINGER INGELHEIM INT (DE) | 2010-10-27 | — | — | EP | disclosed |
| US-20100233268-A1 | POWDER FORMULATIONS FOR INHALATION CONTAINING ENANTIOMERICALLY PURE BETA-AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-7709474-B2 | Enantiomerically pure beta agonists, manufacturing and use thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-7632834-B2 | Long acting beta-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-15 | — | — | US | disclosed |
| EP-2094271-A2 | DRUG COMBINATIONS FOR TREATING AIRWAY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2009-09-02 | — | — | EP | disclosed |
| EP-2056836-A1 | POWDER FORMULATIONS FOR INHALATION CONTAINING ENANTIOMERICALLY PURE BETA-AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2009-05-13 | — | — | EP | disclosed |
| EP-2056837-A1 | AEROSOL FORMULATION FOR THE INHALATION OF BETA-AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2009-05-13 | — | — | EP | disclosed |
| WO-2005070908-A1 | NOVEL LONG-WORKING BETA-2-AGONISTS AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-08-04 | — | — | WO | disclosed |
| EP-0942010-B1 | Transition metal compounds, catalyst components and catalysts for olefin polymerization, and process for producing olefinic polymer | SUMITOMO CHEMICAL CO (JP) | 2003-06-18 | — | — | EP | disclosed |
| US-6500909-B2 | CONTAINING NICKEL, PALLADIUM, RHODIUM, RUTHENIUM, OR COBALT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-12-31 | — | — | US | disclosed |
| US-6410741-B1 | INSECTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-06-25 | — | — | US | disclosed |
| US-20010027162-A1 | Transition metal compound, catalyst component for olefin polymerization, catalyst for olefin polymerization, and process for producing olefinic polymer | HIRAHATA WATARU (JP) | 2001-10-04 | — | — | US | disclosed |
| US-6242377-B1 | POLYMERIZATION IN PRESENCE OF BISOXAZOLINE WITH NICKEL, COBALT, PALLADIUM, RHODIUM, RUTHENIUM, ALUMINUM AND BORON COMPLEXES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-06-05 | — | — | US | disclosed |
| US-6072081-A | Optically active bisoxazoline compounds, production and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-06-06 | — | — | US | disclosed |
| EP-0942010-A1 | Transition metal compounds, catalyst components and catalysts for olefin polymerization, and process for producing olefinic polymers | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-09-15 | — | — | EP | disclosed |
| EP-0137251-B1 | BISMORPHOLINES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTI-HYDROLYSIS AGENTS | BAYER AG (DE) | 1988-09-28 | — | — | EP | disclosed |
| EP-0137251-A2 | Bismorpholines, process for their preparation and their use as anti-hydrolysis agents | BAYER AG (DE) | 1985-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233268-A1 | POWDER FORMULATIONS FOR INHALATION CONTAINING ENANTIOMERICALLY PURE BETA-AGONISTS | ADRB2, ADRB3, ADRB1 | OPRM1 60/4885OPRD1 25/4885OPRK1 39/4885 |
| US-20110053926-A1 | New Pharmaceutically-Active Compounds for the Treatment of Respiratory Diseases | CFTR, SDHA, HRH1 | OPRM1 1041/4885OPRD1 456/4885OPRK1 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.